Flunisolide
Administration
- Type: Inhaled corticosteroid
- Dosage Forms: 80mcg/spray
- Routes of Administration: Inhalation
- Common Trade Names: Aerospan
Adult Dosing
- Inhalation: 2-4 puffs BID
- Max: 640 mcg/day
Pediatric Dosing
- 6-11 yo: 1-2 puffs BID
- Max: 320 mcg/day
- >12 yo: 2-4 puffs BID
- Max: 640 mcg/day
Special Populations
- Pregnancy Rating: D; Possible risk of fetal adrenal suppression; Low risk of teratogenicity
- Lactation risk: L3; Safety unknown
Renal Dosing
- Adult: Not Defined
- Pediatric: Not Defined
Hepatic Dosing
- Adult: Not Defined
- Pediatric: Not Defined
Contraindications
- Allergy to class/drug
- Hypersensitivity to drug/class
- Status asthmaticus
- Asthma, acute
- Avoid abrupt withdrawal
- Bronchospasm, acute
Adverse Reactions
Serious
- Bronchospasm
- Adrenal suppression
- Hypercorticism
- Growth suppression (peds pts)
- Glaucoma
- Cataracts
- Osteoporosis
- erythema multiforme
Common
- URI
- Headache
- Nausea/vomiting
- Dyspepsia
- UTI
- Abdominal pain
- Chest pain
- Infection
- Neck pain
- Diarrhea
- Candidiasis, oral
- Edema
- Myalgia
- Dizziness
- Insomnia
- Voice changes
- Conjunctivitis
- Ear pain
- Taste changes
- Dysmenorrhea
- Vaginitis
Pharmacology
- Half-life: 1.3-1.7 hr
- Metabolism: Liver; CYP450: 3A4 substrate
- Excretion: Urine <1%
Mechanism of Action
Exact mechanism unknown. Inhibits multiple inflammatory cytokines and produces multiple glucocorticoid and mineralocorticoid effects.